This site is intended only for healthcare professionals resident in the Republic of Ireland
In PALOMA-3, IBRANCE in combination with fulvestrant improved tumour response in
IBRANCE in combination with fulvestrant improved tumour response rates vs placebo + fulvestrant in 1st line and later lines, including patients with visceral metastases1,2
In patients with prior resistance to ET and visceral metastases, ORR* was 28% for IBRANCE in combination with fulvestrant (n=200) vs 6.7% with placebo + fulvestrant (n=104)2
See PALOMA-2 tumour response data
Discover how patients responded to IBRANCE combination therapy in the real-world setting
Legal Category: S1A
Further information is available upon request
Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)
Adverse events should also be reported to Pfizer Medical Information on 1800 633 363
Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.
This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie
This website is brought to you by Pfizer Healthcare Ireland, 9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24, Ireland. Registered in the Republic of Ireland No. 127002.
Copyright © 2023 Pfizer Limited. All rights reserved.
The information contained on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland.
I confirm that I am a healthcare professional resident in the Republic of Ireland.*
If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland.
PP-UNP-IRL-0176. January 2023